WHO Drops Hydroxychloroquine From Large COVID-19 Treatment Study, Welcomes Preliminary Results On Dexamethasone But Warns Drug ‘No Cure-All’

STAT: WHO drops hydroxychloroquine from Covid-19 clinical trial
“The World Health Organization on Wednesday said it was dropping the malaria medicine hydroxychloroquine from its massive study investigating treatments for the coronavirus, after available data indicated the drug was not effective for Covid-19…” (Joseph, 6/17).

U.N. News: Welcoming early results on use of dexamethasone in sickest COVID-19 patients, WHO warns it’s ‘no cure-all’
“The U.N. World Health Organization (WHO) on Wednesday hailed news from the United Kingdom that a common steroid, dexamethasone, can potentially help save the lives of patients with severe cases of COVID-19, but it warned that it is by no means a cure-all. Early findings suggest that, for hospitalized coronavirus patients on oxygen, dexamethasone — a low-cost prescription anti-inflammatory drug that is available worldwide — can reduce COVID-19 mortality by about one-fifth…” (6/17).

Additional coverage of the WHO study’s dropping of hydroxychloroquine, early results of dexamethasone to treat seriously ill COVID-19 patients, and other treatment research is available from Becker’s Hospital Review, CIDRAP News, CNBC, NBC (2), Reuters (2) (3), and Xinhua.

The KFF Daily Global Health Policy Report summarized news and information on global health policy from hundreds of sources, from May 2009 through December 2020. All summaries are archived and available via search.

KFF Headquarters: 185 Berry St., Suite 2000, San Francisco, CA 94107 | Phone 650-854-9400
Washington Offices and Barbara Jordan Conference Center: 1330 G Street, NW, Washington, DC 20005 | Phone 202-347-5270

www.kff.org | Email Alerts: kff.org/email | facebook.com/KFF | twitter.com/kff

The independent source for health policy research, polling, and news, KFF is a nonprofit organization based in San Francisco, California.